Indoleamine 2,3-dioxygenase expression predicts impaired survival of invasive cervical cancer patients treated with radical hysterectomy.

[1]  H. Kajiyama,et al.  Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma. , 2009, Gynecologic oncology.

[2]  K. Isobe,et al.  Overexpression of Indoleamine 2,3-Dioxygenase in Human Endometrial Carcinoma Cells Induces Rapid Tumor Growth in a Mouse Xenograft Model , 2008, Clinical Cancer Research.

[3]  D. Munn,et al.  The Indoleamine 2,3-Dioxygenase Pathway Is Essential for Human Plasmacytoid Dendritic Cell-Induced Adaptive T Regulatory Cell Generation1 , 2008, The Journal of Immunology.

[4]  K. Smith-McCune,et al.  Evolving immunosuppressive microenvironment during human cervical carcinogenesis , 2008, Mucosal Immunology.

[5]  H. Kajiyama,et al.  Feasibility and effectiveness of postoperative adjuvant concurrent chemoradiation therapy in Japanese patients with high-risk early-stage cancer of the uterine cervix , 2008, International Journal of Clinical Oncology.

[6]  H. Kajiyama,et al.  Inverse Correlation between Tumoral Indoleamine 2,3-Dioxygenase Expression and Tumor-Infiltrating Lymphocytes in Endometrial Cancer: Its Association with Disease Progression and Survival , 2008, Clinical Cancer Research.

[7]  S. H. van der Burg,et al.  Human Leukocyte Antigen Class I, MHC Class I Chain-Related Molecule A, and CD8+/Regulatory T-Cell Ratio: Which Variable Determines Survival of Cervical Cancer Patients? , 2008, Clinical Cancer Research.

[8]  S. Therasakvichya,et al.  Treatment options in bulky stage IB cervical carcinoma , 2007, International Journal of Gynecologic Cancer.

[9]  J. Nyengaard,et al.  Low density of CD3+, CD4+ and CD8+ cells is associated with increased risk of relapse in squamous cell cervical cancer , 2007, British Journal of Cancer.

[10]  B. Baban,et al.  Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. , 2007, The Journal of clinical investigation.

[11]  J. M. van der Hulst,et al.  Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens , 2007, Proceedings of the National Academy of Sciences.

[12]  B. Monk,et al.  Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  T. Shima,et al.  Expression of indoleamine 2, 3‐dioxygenase and the recruitment of Foxp3‐expressing regulatory T cells in the development and progression of uterine cervical cancer , 2007, Cancer science.

[14]  D. Munn,et al.  Indoleamine 2,3-dioxygenase and tumor-induced tolerance. , 2007, The Journal of clinical investigation.

[15]  L. Moretta,et al.  The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function. , 2006, Blood.

[16]  H. Kajiyama,et al.  Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer , 2006, British Journal of Cancer.

[17]  V. Kesic,et al.  Management of cervical cancer. , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[18]  T. Gajewski.  Identifying and Overcoming Immune Resistance Mechanisms in the Melanoma Tumor Microenvironment , 2006, Clinical Cancer Research.

[19]  Stefan Schneeberger,et al.  Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  N. Yanaihara,et al.  Indoleamine 2,3-Dioxygenase Serves as a Marker of Poor Prognosis in Gene Expression Profiles of Serous Ovarian Cancer Cells , 2005, Clinical Cancer Research.

[21]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[22]  B. Baban,et al.  Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. , 2004, The Journal of clinical investigation.

[23]  N. Singh,et al.  Histopathologic parameters of prognosis in cervical cancer – a review , 2004, International Journal of Gynecologic Cancer.

[24]  C. Uyttenhove,et al.  Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase , 2003, Nature Medicine.

[25]  N. Sakuragi,et al.  Multivariate analysis of histopathologic prognostic factors for invasive cervical cancer treated with radical hysterectomy and systematic retroperitoneal lymphadenectomy , 2002, Acta obstetricia et gynecologica Scandinavica.

[26]  Gerhard Opelz,et al.  Inhibition of Allogeneic T Cell Proliferation by Indoleamine 2,3-Dioxygenase–expressing Dendritic Cells , 2002, The Journal of experimental medicine.

[27]  G. Damonte,et al.  Tryptophan-derived Catabolites Are Responsible for Inhibition of T and Natural Killer Cell Proliferation Induced by Indoleamine 2,3-Dioxygenase , 2002, The Journal of experimental medicine.

[28]  H. Hausen.  Papillomaviruses and cancer: from basic studies to clinical application , 2002, Nature Reviews Cancer.

[29]  V. Abeler,et al.  Tumor size, depth of invasion, and grading of the invasive tumor front are the main prognostic factors in early squamous cell cervical carcinoma. , 1999, Gynecologic oncology.

[30]  F. Landoni,et al.  Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer , 1997, The Lancet.

[31]  G. Fleuren,et al.  Altered HLA expression by metastatic cervical carcinoma cells as a factor in impaired immune surveillance. , 1995, Gynecologic oncology.

[32]  G. Fleuren,et al.  Association between HLA-expression and infiltration of immune cells in cervical carcinoma. , 1993, Laboratory investigation; a journal of technical methods and pathology.

[33]  R. Zaino,et al.  Histopathologic predictors of the behavior of surgically treated stage IB squamous cell carcinoma of the cervix a gynecologic oncology group study , 1992, Cancer.

[34]  O. Takikawa,et al.  Mechanism of interferon-gamma action. Characterization of indoleamine 2,3-dioxygenase in cultured human cells induced by interferon-gamma and evaluation of the enzyme-mediated tryptophan degradation in its anticellular activity. , 1988, The Journal of biological chemistry.

[35]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[36]  J. Nyengaard,et al.  A comparative study of the cellular immune response in patients with stage IB cervical squamous cell carcinoma. Low numbers of several immune cell subtypes are strongly associated with relapse of disease within 5 years. , 2008, Gynecologic oncology.

[37]  Ekaterina S Jordanova,et al.  High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. , 2007, Cancer research.

[38]  H. Nakano,et al.  Multivariate analysis of the histopathologic prognostic factors of cervical cancer in patients undergoing radical hysterectomy , 1992, Cancer.